로딩 중…
지수 로딩 중…
BINEX Co., Ltd.
053030· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,650-3.53%
2026-06-19
Price Chart
BINEX Co., Ltd.-52.25%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 250.03B KRW |
| Revenue | 164.00B KRW |
| Net Income | -3.68B KRW |
| Total Assets | 316.45B KRW |
| Net Assets | 180.02B KRW |
| Employees | 671 |
| Value | |
| P/B | 1.39x |
| P/S | 1.52x |
| Profitability | |
| ROE | -2.04% |
| ROA | -1.16% |
| Op. Margin | -9.67% |
| Revenue Growth | -11.24% |
| Earnings Growth | -77884.55% |
| Financial Health | |
| Debt Ratio | 75.79% |
| Total Debt | 91.87B KRW |
| Cash | 22.36B KRW |
| Current Ratio | 1.50x |
| Performance | |
| 1Y Return | -52.25% |
| 1M Return | -15.38% |
| From 52W High | -60.16% |
| 1Y MDD | -59.44% |
| Trading | |
| Volume | 134,748 shares |
| Foreign Own. | 8.23% |
| Per Share | |
| EPS | -393 KRW |
| BPS | 5,648 KRW |
Company Info
Established in 1957, the company changed its name to Binex in 2000, listed on KOSDAQ in 2001, and expanded its business in 2015. It operates chemical pharmaceutical manufacturing and biopharmaceutical CDMO businesses, producing over 120 products in Busan and providing CDMO services in Songdo and Osong. To advance as a global CDMO, the company has passed GMP audits and plans to obtain cGMP certification and expand production capacity through an FDA audit in 2025, solidifying its standing as a global bio hub. Binex is headquartered in Saha-gu, Busan.